We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
French pharmaceutical company Ipsen has announced that The New England Journal of Medicine has published the results of a Phase II clinical trial of liver cancer drug Cabometyx (cabozantinib).